EIF2AK3 and hepatocellular carcinoma: Recently, Li et al. found that phosphorylated ERK (pERK) and pAkt expressions in CTCs were correlated to sorafenib efficacy in HCC patients, and pERK+/pAkt− CTCs were the most sensitive CTCs in response to sorafenib.